For the palliative treatment of patients with advanced prostatic carcinoma.

For the treatment of symptoms associated with irritable bowel syndrome.

For use in combination treatment of HIV infection (AIDS).

For the treatment of serious bacterial infections in hospitalised patients.

For the treatment of hypertension.

For the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

Intended for the treatment of various forms of cancer.

Intended for the treatment of various forms of cancer.

Investigated for use/treatment in crohn's disease, inflammatory bowel disease, and ulcerative colitis.

Investigated for use/treatment in kidney disease and psoriasis and psoriatic disorders.

April 18 2007 Cortex Pharmaceuticals submitted two large data packages to the FDA regarding CX717. One data set went to the FDA's Division of Neurology Drug Products for the ...

Investigated for use/treatment in pain (acute or chronic).

Investigated for use/treatment in multiple sclerosis.

Investigated for use/treatment in depression.

Investigated for use/treatment in leukemia (myeloid) and solid tumors.

Investigated for use/treatment in nephropathy.

Investigated for use/treatment in solid tumors.

Investigated for use/treatment in bladder cancer.

Investigated for use/treatment in alzheimer's disease.

Investigated for use/treatment in pain (acute or chronic).